Gene · 440
ASNS: asparagine synthetase (glutamine-hydrolyzing)
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ASNS: asparagine synthetase (glutamine-hydrolyzing). Genes, record 440. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/440
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P08243 | Asparagine synthetase [glutamine-hydrolyzing] | 561 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 37945 | P08243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37946 | P08243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37947 | P08243 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 154 | P08243 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 124 | P08243 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4293 | P08243 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 124 | P08243 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 154 | P08243 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6669 | P08243 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6670 | P08243 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,237
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ASNS papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 22 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| ZIADA000618 | Cellular mechanisms of neuronal dysfunction in addiction and neurodegeneration | 5 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 4 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 4 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 4 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 4 | 2025 |
1 to 10 of 1,237Source NIH's project files
See all 1,237 nih grantsPapers1,669
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| α-aminobutyric acid promotes tumor progression by polarizing macrophages through the ASNS-mTORC2 axis. | Proc Natl Acad Sci U S A | 2026 | 42814553 | PubTator, text mining | PubMed |
| Asparagine Synthetase Deficiency: Neuropathological Evidence of Disrupted Cortical Development. | JIMD Rep | 2026 | 42741518 | PubTator, text mining | PubMed |
| GPT2 enhances colorectal cancer cell growth, movement, and invasion by altering gene expression patterns. | Tissue Cell | 2026 | 42691609 | PubTator, text mining | PubMed |
| Disulfidptosis- and Ferroptosis-Related Gene Signatures in Rheumatoid Arthritis: Association Analysis and Diagnostic Model Construction. | Kaohsiung J Med Sci | 2026 | 42690169 | PubTator, text mining | PubMed |
| Integrative bulk and single-cell transcriptomics identify a recurrence-prognostic risk model with exploratory associations with treatment-response phenotypes in colorectal cancer. | Hum Cell | 2026 | 42606648 | PubTator, text mining | PubMed |
| Asparagine synthetase deficiency: clinical features and experience with asparagine supplementation. | J Pediatr Endocrinol Metab | 2026 | 42568280 | PubTator, text mining | PubMed |
| IGSF3 drives acquired temozolomide resistance in glioblastoma through ASNS-dependent asparagine biosynthesis. | J Biol Chem | 2026 | 42486263 | PubTator, text mining | PubMed |
| The MAPK/ATF3/ASNS axis drives amino acid metabolic reprogramming to promote NSCLC survival under glucose deprivation. | J Transl Med | 2026 | 42436529 | PubTator, text mining | PubMed |
| Exploring key genes and prognostic validation of prostate cancer through transcriptome-wide association study. | Sci Rep | 2026 | 42401728 | PubTator, text mining | PubMed |
| From ALL to Myeloid and NK Malignancies: Operationalizing "ASNS-Low" for L-Asparaginase Repurposing and Combination Therapy. | Biomolecules | 2026 | 42352259 | PubTator, text mining | PubMed |
1 to 10 of 1,669
See all 1,669 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/440
GET https://conductscience.org/api/genes/v1/440/patents?page=2